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Abstract
Background: Interferon-a (IFN) induces complete cytogenetic remission (CCR) in 20–25% CML patients and in a small
minority of patients; CCR persists after IFN is stopped. IFN induces CCR in part by increasing cytotoxic T lymphocytes (CTL)
specific for PR1, the HLA-A2-restricted 9-mer peptide from proteinase 3 and neutrophil elastase, but it is unknown how CCR
persists after IFN is stopped.
Principal Findings: We reasoned that PR1-CTL persist and mediate CML-specific immunity in patients that maintain CCR
after IFN withdrawal. We found that PR1-CTL were increased in peripheral blood of 7/7 HLA-A2+ patients during
unmaintained CCR from 3 to 88 months after IFN withdrawal, as compared to no detectable PR1-CTL in 2/2 IFN-treated CML
patients not in CCR. Unprimed PR1-CTL secreted IFNc and were predominantly CD45RA6CD28+CCR7+CD57-, consistent
with functional naı ¨ve and central memory (CM) T cells. Similarly, following stimulation, proliferation occurred predominantly
in CM PR1-CTL, consistent with long-term immunity sustained by self-renewing CM T cells. PR1-CTL were functionally
anergic in one patient 6 months prior to cytogenetic relapse at 26 months after IFN withdrawal, and in three relapsed
patients PR1-CTL were undetectable but re-emerged 3–6 months after starting imatinib.
Conclusion: These data support the hypothesis that IFN elicits CML-specific CM CTL that may contribute to continuous CCR
after IFN withdrawal and suggest a role for T cell immune therapy with or without tyrosine kinase inhibitors as a strategy to
prolong CR in CML.
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Introduction
Since the introduction of interferon-a (IFN) as a treatment for
CML [1,2], randomized trials have shown that it is able to induce
hematological remission in 70–80% cases and cytogenetic remission
in 35–55% cases [3]. IFN also induces complete cytogenetic
remission (CCR) in 13% of patients, of which over approximately
50% are durable for 2–8 years [4]. Studies have shown that IFN-
treated chronic phase patients in complete or sustained cytogenetic
remission (CR) still have significant (1–12%) numbers of BCR-ABL
positive cells [5,6,7], identified by fluorescence in situ hybridization
(FISH) or by quantitative real time-PCR (QR-PCR) of the BCR-
ABL fusion gene [6,8,9]. In patients with blast crisis CML, CFU-
BM may be the reservoir of leukemia stem cells (LSCs) [10]. These
cells are not likely to be eliminated by traditional chemotherapy or
by tyrosine kinase inhibitors [11]. Conversely, after IFN is
discontinued, a small number of patients remain in cytogenetic or
molecular remission for months to years without treatment [12],
suggesting possible elimination of CML, or the persistence of
residual undetectable LSC, which may be intrinsically constrained,
controlled by indirect mechanisms that suppress growth, or both.
Previous studies showed that IFN directly inhibits CML cells
[13,14], although this mechanism cannot explain persistence of
cytogenetic or molecular remission many years after stopping IFN.
As an alternative mechanism, IFN induces specific immunity
against CML and T cells specific for leukemia-associated antigens
(LAA) can target leukemia progenitors and contribute to
CR[15,16]. These observations suggest that long-term leukemia-
specific immunity may prevent future outgrowth of CML or may
even eliminate leukemia. It is not possible to predict which patients
will continue in CR after stopping IFN, and previous studies have
not examined suchpatients to determine whether immunity to LAA
persists after IFN withdrawal.
One such LAA is the HLA-A2-restricted PR1 peptide
(VLQELNVTV), which is derived from proteinase 3 (P3) and
neutrophil elastase (NE), differentiation stage-specific serine
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leukocytes [17]. P3 is over-expressed in a variety of myeloid
leukemias, including 75% of CML patients, [18] and may be
involved in the process of leukemia transformation or maintenance
of the leukemia phenotype [19] via the proteolytic regulation of
the cyclin dependent kinase inhibitor p21
waf1 [20]. P3 is expressed
in CML progenitors and PR1-specific cytotoxic T lymphocytes
(CTL) kill leukemia cells [21] and inhibit HLA-A2
+ CML colony
forming units in proportion to over-expression of P3 in leukemia
cells as compared to normal bone marrow cells [15]. Interestingly,
the expression of P3 and NE in CD34+ CML cells correlated with
improved clinical outcomes after treatment with allogeneic stem
cell transplantation or IFN therapy, potentially due to improved
PR1-specific anti-leukemia effects [22,23]. Importantly, PR1-CTL
are increased and contribute to CCR in CML patients receiving
IFN, but they are not detected in patients at relapse despite
continuous treatment with IFN [16]. In addition, PR1-CTL
expressing either high or low avidity T cell receptors can be
expanded from healthy donor peripheral blood and TCR avidity
correlates with CTL effector function [24], similar to T cell
immunity to foreign antigens [25,26,27,28]. Importantly, CML
cells that overexpress P3 can shape host immunity by inducing
apoptotic deletion of high avidity PR1-CTL, which results in loss
of functional immunity to CML [24]. Moreover, both P3 target
antigen and PR1-CTL were found to be increased in CML
patients that continued in CCR while receiving IFN as a single
agent maintenance therapy after first achieving CCR during
upfront treatment with IFN plus the bcr-abl tyrosine kinase
inhibitor imatinib mesylate [29]. This suggests that continuous
IFN treatment may maintain CCR by increasing PR1-CTL
immunity, although the effect of further IFN withdrawal on
persistent PR1-CTL immunity and CCR status is not known.
Therefore, we hypothesized that functional memory PR1-CTL
may persist in some patients via long-term self-renewal mecha-
nisms that work to maintain CCR after IFN withdrawal. Here we
report that PR1-specific CTL are increased and persist in the
peripheral blood of CML patients during unmaintained CCR
after stopping IFN and that PR1-CTL secrete IFNc. Although
surprisingly enriched in phenotypically naı ¨ve cells, the central
memory (CM) PR1-CTL subset showed robust antigen-induced
proliferation. Our data suggest that IFN may induce the expansion
of memory PR1-CTL with self-renewing capacity in a subset of
patients in unmaintained CCR, which may be critical for effective
long-term immunity to CML, thereby sustaining CCR in CML
patients after IFN withdrawal.
Materials and Methods
Ethics Statement
All donors and patients were enrolled on a study protocol that
was reviewed and approved by the University of Texas M. D.
Anderson Cancer Center (MDACC) Institutional Review Board
and provided written informed consent to participate.
Patients
Seven patients that had an established diagnosis of chronic
phase CML based on presence of Philadelphia chromosome, were
HLA-A2
+ and in complete cytogenetic remission (CCR) that was
induced by IFN treatment, and two chronic phase CML patients
that did not respond to IFN were studied (Table 1). Three
patients (patients 3, 4, and 6) had a molecular CR documented by
absence of BCR-ABL transcripts by quantitative real time-
polymerase-chain-reaction (QR-PCR), standardized in the De-
partment of Hematopathology at M. D. Anderson Cancer Center.
RNA was analyzed by QR-PCR to quantitate BCR-ABL and ABL
transcripts and transcript levels reported on the International Scale
(IS). Cytogenetic relapse occurred in 3 patients (patients 2, 6, and
7) after IFN withdrawal, which was treated with imatinib
monotherapy, 400 mg daily. Cytogenetic response was assessed
by G-banding and counting Ph-positive metaphases in at least 20
cells in metaphase per bone marrow biopsy sample. Median
disease duration was 5 years (range of 1 to 7 years). Patients who
had previously discontinued IFN treatment, most often due to
constitutional side effects, and who remained in CCR, were
selected for this study. Prior to study, patients had not received any
treatment for CML for 6–88 months.
After informed consent, peripheral blood mononuclear cells
(PBMC) from patients were obtained at various time points during
their routine clinic follow up, approximately every six months. The
cells were separated using Ficoll-Histopaque gradient-density
(Organon Teknika Corp., Durham, North Carolina, USA) and
subsequently cryopreserved in RPMI-1640 complete medium
(CM) (25 mM HEPES buffer, 2 mM L-glutamine, 100 U/ml
penicillin, 100 mg/ml streptomycin; Life Technologies Inc.,
Table 1. Baseline patient characteristics.
Patient Number Sex Age Sokal






1 F 63 Low 14 118 1
2 M 46 Int 89 365 2
3 M 52 Low 23 480 1
4 F 28 Low 46 192 1
5 F 32 Low 18 258 0
6 M 53 Int 69 598 1
7 F 55 Int 112 742 2
8 M 62 Low 38 633 1
9 F 59 High 183 879 3
1The Sokal score is based on age, spleen size, peripheral blood platelet count, and blast count. Patients are classified as being low-risk (Sokal score ,0.8), intermediate-
risk (0.8 to 1.2), or high-risk (.1.2).
2The Eastern Cooperative Oncology Group (ECOG) performance status is graded on a scale of 0 to 5, with 0 indicating that the patient is fully active and able to carry on
all pre-disease activities without restriction and 5 indicating that the patient has died.
Characteristics of patients at the time of newly diagnosed Philadelphia chromosome-positive (Ph+) chronic-phase CML.
doi:10.1371/journal.pone.0011770.t001
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inactivated pooled human AB serum (AB; Sigma-Aldrich, St.
Louis, Missouri, USA) and 10% DMSO, according to standard
protocols. Before use, cells were thawed at 37uC, washed and
suspended in CM plus 10% AB.
HLA Testing
HLA-A2 expression was confirmed with the BB7.2 antibody,
which is specific for the HLA-A*0201 allele. One million PBMC
were washed 3 times in PBS and stained with the BB7.2 antibody
for 25 minutes on ice, washed again and stained with FITC-
labeled goat-anti-mouse secondary antibody (Becton Dickinson
Immunocytometry Systems, San Jose, California, USA) for 30
minutes at 4uC in the dark. Cells were washed twice in PBS and
re-suspended in PBS +1% paraformaldehyde (PFA). All samples
were acquired within 24 hours of staining, using a FACScan flow
cytometer and CellQuest software. At least 25000 events were
collected.
Peptide Synthesis
PR1 (aa 169–177) peptide (VLQELNVTV) is derived from the
azurophilic granule protein proteinase 3. The cytomegalovirus
(CMV) peptide (NLVPMVATV) is derived from pp65, the
immunodominant antigen from CMV. Both peptides were
synthesized by the MD Anderson Cancer Center Synthetic
Antigen Laboratory (Houston, Texas) to a minimum of 95%
purity as measured by high performance liquid chromatography.
Tetramer Synthesis
A 15-amino acid substrate peptide (BSP) for BirA-dependent
biotinylation has been engineered onto the C-terminus of HLA-
A2. The A2-BSP fusion protein and human b2-microglobulin
(b2M) were expressed in Escherichia coli, and were folded in vitro
with the specific peptide ligand. The properly folded MHC-
peptide complexes were extensively purified using FPLC and
anion exchange, and biotinylated on a single lysine within the BSP
using the BirA enzyme (Avidity, Denver, Colorado). Tetramers
were produced by mixing the biotinylated MHC-peptide com-
plexes with phycoerythrin (PE)-conjugated Neutravidin (Molecular
Probes, Eugene, Oregon) at a molar ratio of 4:1. PR1 tetramers
were validated by staining PBMC from patients immunized with
the PR1 peptide. CMV tetramers were validated by staining
PBMC from a CMV-immune subject. The concentration of each
tetramer used in this study was individually determined, and was
generally 40–50 mg/ml.
Cytokine Flow Cytometry
PBMC were washed 2 times in serum free Ex-Vivo (BioWhit-
taker, Walkersville, MD) re-suspended at 10610
6 cells/ml in CFC
media (Ex-Vivo +5 mg/ml CD28 +2.5 mg/ml CD49d (BD
Biosciences, Immunocytometry Systems, San Jose, CA)). PBMC
were plated at 1610
6 cells/well and incubated with PR1 (0.2 mM,
2 mM, 20 mM and 200 mM) or pp65-A2 (20 mM) in a total volume
of 200 mL/well. Un-stimulated cells were used to set background
and Staphylococcal Enterotoxin B (SEB, Sigma-Aldrich, St. Louis,
MO), a non-specific T cell activator, was used at 5 mg/ml as a
positive control. Plates were incubated at 37uC and 5% CO2 for
1 hour, Brefeldin A was added to a final concentration of 10 mg/
ml and incubation continued for an additional 5 hours. Cells were
then washed once in PBS and incubated in PBS +0.02% EDTA
(Sigma-Aldrich, St. Louis, MO) at 37uC and 5% CO2 for 15
minutes. Cells were washed once with cold PBS and treated with
1x FACS Lysing Solution (BD Biosciences, Immunocytometry
Systems, San Jose, CA) for 10 min at room temperature. Cells
were centrifuged and treated with 1x FACS Permeabilizing
Solution (BD Biosciences, Immunocytometry Systems, San Jose,
CA) for 10 min at room temperature. Cells were then washed 2
times in wash buffer (PBS +1% BSA and 0.02% NaN3). Cells were
incubated with anti-CD8, anti-IFNc and anti-CD69 (both from
BD Biosciences, Immunocytometry Systems, San Jose, CA) for
30 min at 4uC in the dark, washed 2 times in wash buffer and re-
suspended in PBS +1% PFA. All samples were acquired within
24 hours of staining, using a FACScan flow cytometer and
CellQuest software. At least 50,000 events were acquired and
gating was done on small lymphocytes and CD8+ cells.
T cell Phenotyping and Sorting
Titrated PR1/HLA-A2 tetramer was used to identify and
distinguish between high and low avidity PR1-CTL, defined by a
1-log separation in fluorescence intensity [24]. 1610
6 PBMC were
washed 3 times in PBS and surface stained with CD8 as well as
CD14, CD16 and CD19 (all from Caltag Labs, Burlingame, CA)
at 4uC for 30 minutes. CD14, CD16 and CD19 were used to
exclude monocytes, NK cells and B cells from analyses. After
washing, the cells were then incubated with 40–50 mg/ml of PE-
labeled PR1/HLA-A2 tetramer at 4uC for 40 minutes, washed
twice in PBS and fixed in 2% PFA. Cells were analyzed on a BD
FACScan using CellQuest software. At least 80,000 events were
collected.
For higher order multi-parameter phenotyping and cell sorting,
the PBMC were thawed at 37uC, washed twice in PBS and re-
suspended at 10610
6 cells/ml. A cocktail of appropriate antibody
combinations of up to 8 unique colors from the following was used
for staining cells: CD28, CD16 (Beckman Coulter, Miami, FL),
CD8, CD14, CD16, CD19, CD45RA (Caltag Labs, Burlingame,
CA), CD45RA, CD45RO, CD57, CCR7, CD27 (BD Pharmin-
gen, San Diego, CA), CD4, CD45RA (BD Immunocytometry
Systems, San Jose, CA) and CD45RA (Beckman Coulter, CA).
When the multi-color combinations required it, CD45RA or
CD27 was conjugated to Zenon
TM Alexa350, or Zenon
TM
Pacific
Blue (Molecular Probes, Eugene, OR). Cells were stained
simultaneously with up to 8 antibodies in a cocktail for 25 minutes
at 4uC in the dark. After washing twice in PBS, cells were stained
with 40–50 mg/ml PE-conjugated PR1/HLA-A2-tetramer for 40
minutes at 4uC in the dark, washed twice in PBS and fixed in PBS
+1% PFA. Single antibody stained cells were used to set
compensation. Data was acquired on a MoFlo flow cytometer
(Dako Cytomation, Fort Collins, CO), a Cyan flow cytometer
(Dako Cytomation, Fort Collins, CO), or a FACSAria cytometer
(BD Immunocytometry Systems, San Jose, CA) and analyzed
using FlowJo analysis software (Treestar Inc, San Carlos, CA). Cell
sorting was done on a FACSAria cytometer using the FACS Diva
Software (BD Immunocytometry Systems, San Jose, CA).
CFSE Cell Proliferation Assay
Cell proliferation was measured using carboxyfluorescein
diacetate succinimidyl ester (CFSE, Molecular Probes, Eugene,
OR) labeling. A 10 mg/ml stock solution of CFSE was prepared in
dry DMSO (Sigma-Aldrich, St. Louis, MO) and stored at 220uC
in 10 mL single-use aliquots. A working solution was prepared by
diluting the stock solution with 990 mL dry DMSO. Up to 2.5610
6
PBMC or sorted cells were washed with PBS and re-suspended in
1 ml PBS at room temperature. 15 mLo f1 0mg/ml CFSE was
added and cells were incubated at 37uC for 8 minutes. Labeling
was quenched with FBS. Cells were washed in PBS and incubated
in media (Ex-Vivo+10%AB) for 5 minutes at 37uC. Cells were
then washed with media, re-suspended in 1 ml media and
T Cells Maintain CML Remission
PLoS ONE | www.plosone.org 3 July 2010 | Volume 5 | Issue 7 | e11770stimulated with 20 mM PR1, or 50 ng/ml purified anti-CD3
(OKT3, Ortho-Biotech, Bridgewater, NJ) and 1 mg/ml anti-CD28
(BD Biosciences). IL-2 (R&D Systems) was added at 100 IU/ml to
each well and un-stimulated cells were used to define CFSE
intensity in undivided cells. Cells were incubated at 37uC and 5%
CO2 for 80 hours and analyzed for proliferation by FACS. For
analysis of surface phenotype after proliferation, cells were washed
once with PBS and incubated with previously titrated amounts of
antibodies to CD4, CD14, CD16, CD19, CD8, CD45RA, CCR7
and CD25 for 30 min at 4uC. After washing twice in PBS, cells
were stained with 40–50 mg/ml PE-conjugated PR1/HLA-A2-
tetramer for 40 minutes at 4uC in the dark, washed twice in PBS
and fixed in PBS +1% PFA. Cells were acquired on a FACSAria
cytometer or a Cyan cytometer. Single stained controls were used
to set compensation and the data was analyzed using FlowJo. Cell
divisions are measured by successive 2-fold dilution in CFSE
intensity and represent a 2-fold increase in frequency. To estimate
the frequency of cells that proliferated, the proportion of cells in
each CFSE dilution peak was divided by 2
n (where n is the number
of the cell division) and summed. To calculate proliferation index
or average number of divisions per cell, the frequency of cells that
proliferated in each division was normalized to 1, multiplied by the
division number and summed.
Statistical Analysis
A paired, two-tailed Student’s t-test (95% confidence interval)
was used to determine statistical significance of differences
between samples. All data are represented as mean 6 standard
error.
Results
PR1-CTL persist in IFN-sensitive CML patients after IFN
withdrawal
Previously, we have shown that PR1-CTL are found in most
patients that achieve remission while being treated with IFN and
that these PR1-CTL contribute to remission by killing CML cells
[16]. Since 1–3% of patients that achieve remission do not relapse
after IFN has been withdrawn, we hypothesized that PR1-CTL
may contribute to the maintenance of remission in patients who
remain in cytogenetic remission after IFN withdrawal. In order to
determine whether PR1-CTL persist in the peripheral blood of
Table 2. Patient disease responses and PR1-CTL immune responses.
Patient
number








%o fI F N c+ CD8
cells (+PR1)
%o fI F N c+ CD8
cells (+SEB)
1 42 18 0.39 0.3 — —
26 0.077 0.74 — —
2 80 15 0.035 0.53 0.18 4.97
21 0.22 0.19 ,0.01 7.96
26* 8.1 ,0.01 ,0.01 6.34
32* 0.67 0.25 0.1 3.89
38* 0.066 2.17 — —
3 98 45 0 0.83 2.63 7.04
53 0 0.72 0.05 1.58
60 0 2.11 0.06 3.45
4 108 75 0 0.89 0.06 5.21
88 0 0.78 0.08 2.31
5 82 12 0.0039 2.73 2.2 15.27
24 0.0041 1.53 2.5 21.59
6 69 0 0.088 0.33 — —
6 0.0011 1.46 3.83 14.09
14* 2.4 0.03 ,0.01 14.6
7 50 3 0.21 0.15 0.1 4.66
11* 11.3 0.02 ,0.01 5.27
14* 0.16 0.31 0.19 6.2
8 8 NA 26.5 ,0.01 — —
14 NA 21.4 ,0.01 — —
9 6 NA 11.6 0.02 — —
9 NA 15.7 ,0.01 — —
*Patient receiving imatinib 400 mg daily.
2Denotes that the result that could not be determined due to an insufficient number of cells.
NA Not applicable since IFN was not withdrawn in these patients.
BCR-ABL transcripts were determined with quantitative real-time PCR (RQ-PCR) of peripheral blood, as expressed on the International Scale (IS). PR1/HLA-A2 tetramers
were used to enumerate PR1-CTL in PBMC, and PBMC were left unstimulated or stimulated with either the PR1 peptide or with SEB and analyzed for IFNc production by
flow cytometry. Shown are the frequencies of CD8+ T cells that produce IFNc, after subtracting percentage of CD8+ cells that stain positive for IFNc without any
stimulation. The highest frequency of CD8+ cells that produce IFNc when stimulated with PR1 are shown.
doi:10.1371/journal.pone.0011770.t002
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retrospectively studied available PBMC from nine HLA-A2+
CML patients that were treated with IFN 3-times weekly as first-
line therapy. Patient characteristics at time of diagnosis are shown
in Table 1. All patients were diagnosed with chronic phase CML,
and four patients had intermediate or high Sokal scores.
Seven patients achieved CCR, then IFN was withdrawn and
patients received no maintenance therapy. Three patients
subsequently developed cytogenetic relapse (patients 2, 6, and 7)
and were treated with imatinib, as summarized in Table 2. Two
patients (patients 8 and 9) did not achieve CCR while receiving
IFN. Complete molecular remission was noted in patients 3 and 4,
and increased circulating PR1-CTL persisted during the study
period (12–15 months).
Figure 1 shows the clinical status of the seven HLA-A2+
patients over time relative to the date of IFN withdrawal. From
available archived samples, PBMC were stained with CD8, CD14,
CD16, and CD19 antibodies, followed by staining with the PR1/
HLA-A2 or pp65/HLA-A2 tetramers. All patients in cytogenetic
remission (patients 1, 2, 5, and 7) and all patients in molecular
remission (patients 3, 4 and 6) had detectable PR1-CTL in their
peripheral blood (Table 2). The frequency of PR1-CTL as a
percentage of CD8+ cells relative to time after IFN withdrawal is
shown in Figure 2 for each of the seven patients studied. At the
time of cytogenetic relapse (patients 2, 6, and 7), the previously
detectable PR1-CTL were no longer detectable.
PR1-CTL are functional and secrete IFNc
In order to assess whether the PR1-CTL were functional, when
sufficient cells were available for analysis we incubated PBMC in
media overnight prior to stimulation with PR1 peptide and
measured IFNc production by CD8+ T cells using cytokine flow
cytometry in a 6 hour assay. Corresponding to time points after
IFN withdrawal for each patient, Table 2 shows the disease
burden by BCR-ABL transcripts and the frequencies of PR1-CTL
and of CD8+ cells that produce IFNc when stimulated with either
PR1 or SEB. Cells were stimulated with 4 different PR1
concentrations and the table shows the highest frequency of cells
producing IFNc. All patients that maintained remission (patients
3, 4, and 5) maintained a measurable functional response to PR1
at all times sampled after IFN withdrawal.
PR1-CTL express all T cell differentiation phenotypes
The pattern of lineage differentiation phenotype of antigen-














2, though this pattern may
in part depend upon the antigen specificity of the CTL. This final
stage of maturation has been associated with a non-proliferating
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phenotype upon antigen stimulation, suggesting that there is a
memory T cell population that can undergo expansion and ensure
continuous replenishment of the effector cell pool. Furthermore,
although the phenotype of the population of CD8+ T cells with
replication senescence is not well described [31,32], CD57
expression without CD28 or CCR7 expression has been shown
to define terminally differentiated T cells [33].
To determine whether all lymphocyte differentiation pheno-
types were present, we assessed the surface phenotype of PR1-
CTL from all of the patients. Figure 3A shows a representative
PR1-CTL phenotype from patient 3, 60 months after IFN
Figure 1. Longitudinal disease burden of CML patients in complete cytogenetic remission (CCR) after withdrawal of IFN treatment.
Disease characteristics of seven HLA-A2+ patients in whom IFN treatment was withdrawn. Patients received IFN starting from the time of diagnosis
(left-most time point) until it was stopped (denoted as time=0). For each patient, closed bars denote time points when any Ph+ chromosome was
detected in bone marrow, open bars denote time points when no Ph+ chromosomes were detectable (complete cytogenetic remission, CCR) but
BCR-ABL transcripts were detectable by QR-PCR, and the solid line denotes time points when BCR-ABL transcripts were not detectable (complete
molecular remission). Arrows denote when certain patients received imatinib monotherapy.
doi:10.1371/journal.pone.0011770.g001
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percentage of PR1/HLA-A2 tetramer-negative CD8
+ lympho-
cytes (CD8+) and the PR1/HLA-A2 tetramer-positive CD8
+
(PR1-CTL) that express central memory (CD45RA-
CCR7+CD28+) or naı ¨ve (CD45RA+ CCR7+CD28+) phenotypes,
averaged from all of the patients. Although there was no significant
difference in the percentage of CD8+ lymphocytes and PR1-CTL
that expressed the central memory phenotype (p=0.2981), the
PR1-CTL population was enriched for cells expressing the naı ¨ve
phenotype as compared with the overall CD8+ lymphocyte
population (p=0.0217). Furthermore, none of the PR1-CTL
expressed CD57 in any of the patients studied (data not shown).
Since PR1-CTL did not express CD57 and were capable of
producing IFNc when stimulated with the PR1 peptide, together
these data show that PR1-CTL from these patients are not
anergic.
PR1-CTL with central memory phenotype retain self-
renewal capacity
A discrete population of PR1-CTL from all patients express a
phenotype consistent with memory T cells. We hypothesized that
PR1-CTL from IFN-sensitive CML patients consists of a self-
renewing memory T cell population. To determine whether PR1-
CTL could proliferate, we labeled PBMC from patient 3 with
CFSE, added an equal number of cells per well and stimulated
them with OKT3, anti-CD28 and IL-2. To assess the surface
phenotype of proliferating PR1-CTL, the cells were labeled with
the PR1/HLA-A2 tetramer and antibodies to CD8, CD45RA,
CCR7 and CD25 after stimulation and analyzed by flow
cytometry. Figure 4 shows that in the absence of stimulation,
PR1-CTL underwent cell death and could not be identified.
However, with CD3/CD28/IL-2 stimulation, PR1-CTL prolifer-
ate robustly and the largest fraction of proliferating PR1-CTL
express a phenotype consistent with central memory T cells. We
compared the phenotype of PR1-CTL before and after stimulation
and determined that although prior to stimulation a majority of
PR1-CTL expressed a naı ¨ve T cell phenotype, after proliferation
the PR1-CTL were predominantly central memory T cells
(Figure 4).
While the results in Figure 4 support our hypothesis that
memory PR1-CTL proliferate, labeling to identify phenotypes
after proliferation may have biased the results toward cells that
undergo multiple cell divisions or that re-express CCR7.
Therefore, to determine whether the central memory PR1-CTL
could proliferate, we sorted CD8+ T cells from patient 4 into 4
Figure 2. PR1-CTL persist in patients that maintain remission after IFN withdrawal. For each patient, the panel shows the total percentage
of CD8+ cells that were identified with the PR1/HLA-A2 tetramer at time points after IFN withdrawal.
doi:10.1371/journal.pone.0011770.g002
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each. CD8+ T cells were sorted into the following populations:
CD45RO+CD45RA-CCR7+ (central memory), CD45RO+C-
D45RA-CCR7- (effector), CD45RO-CD45RA+CCR7+ (naı ¨ve)
and CD45RO-CD45RA+CCR7- (terminally differentiated). After
sorting, cells were labeled with CFSE and stimulated for 80 hours.
Cells were then stained with tetramer and analyzed for
proliferation. For each cell population, the fraction of cells that
diluted CFSE was analyzed and the frequency of cells that
proliferated was calculated. We found that that the frequency of
effector and central memory PR1-CTL that proliferated was
similar to the frequency of the overall CD8+ that proliferated
(Figure 5A). We also found that a higher frequency of naı ¨ve PR1-
CTL proliferated as compared with the overall CD8+ population.
We next compared the proliferation index or average number of
divisions per cell of PR1-CTL with the overall CD8+ cells in each
sub-population. Figure 5B also shows that the proliferation
indices for the naı ¨ve, effector and central memory PR1-CTL were
approximately 2.5 whereas the proliferation index for the
terminally differentiated PR1-CTL was 4.4. Senescent T cells
have been shown to express CD57 [33] and PR1-CTL from IFN-
sensitive CML patients off all therapy do not express CD57 (data
not shown), indicating that PR1-CTL with a terminally differen-
tiated phenotype are not senescent. These data also suggest that
there is a self-renewing PR1-CTL population that may contribute
to maintaining remission in this subset of patients.
Loss of functional PR1-CTL immunity occurs prior to
cytogenetic relapse
Patient 2 relapsed 26 months after IFN withdrawal. Following
relapse, the patient was treated with imatinib (Table 2). We
hypothesized that functional PR1-CTL would be observed prior to
relapse that would be selectively lost at relapse. We assessed the
persistence of PR1-CTL after IFN withdrawal by staining with
PR1/HLA-A2 tetramer and determined whether the PR1-CTL
were functional by assessing intra-cellular IFNc production in
response to stimulation with the PR1 peptide at varying
concentrations. At 15 months after IFN withdrawal, patient 2
remained in CCR and had functional high and low avidity PR1-
CTL (Figure 6) that exhibited a memory phenotype (as shown in
Figure 3). Of the CD8
+ cells, 0.18% showed IFNc production in
response to stimulation with 0.2 mg/ml PR1 peptide. At 21
months after IFN withdrawal, the patient remained in CCR and
had 0.19% PR1-CTL. However, PR1-CTL did not produce IFNc
in response to stimulation with the PR1 peptide at concentrations
Figure 3. PR1-CTL express all T cell differentiation phenotypes. A cocktail of antibodies with 8 fluorochromes was used to label PBMC with
anti-CD8, lineage markers (Lin; anti-CD4, anti-CD14, anti-CD16, anti-CD19), CCR7, CD27, CD45RA, CD28, CD57 and PR1/HLA-A2 tetramer. The data was
analyzed using the FlowJo analysis software. (A) Gating was done on CD8+ Lin- lymphocytes in the upper panel and on PR1-CTL in the center and
lower panels. The center and lower panels show the representative phenotype of naı ¨ve and memory PR1-CTL from patient 3. The percentage of PR1/
HLA-A2 tetramer-negative and PR1/HLA-A2 tetramer-positive CD8+ cells that express (B) central memory or (C) naı ¨ve phenotype averaged from
patients 1 to 7 is shown. P-values were calculated using a two-tailed t-test and results are shown as mean 6 SEM.
doi:10.1371/journal.pone.0011770.g003
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although CD8+ T cell responses to SEB were maintained. This
shows a selective loss of functional PR1-CTL. Five months later, at
26 months after IFN withdrawal, patient 2 had a cytogenetic
relapse with 35% Ph
+ cells and PR1-CTL were no longer
detectable. Furthermore, PR1-CTL that were increased after
stopping IFN were either not detectable or at the lower limit of
detection in patients 6 and 7 at time of cytogenetic relapse
(Table 2). Similarly, PR1-CTL were also not functional at the
time of cytogenetic relapse (Table 2). Interestingly, after the three
patients were started on imatinib, PR1-CTL once again increased
and secreted IFNc. In contrast, PR1-CTL were not detectable in
patients 8 and 9 that did not achieve CCR during IFN therapy.
Thus, patients who relapse after IFN withdrawal may preferen-
tially loose functional PR1-CTL immunity prior to the decrease in
total PR1-CTL.
Discussion
Although direct effects of IFN on CML cells have been
described as a mechanism of inducing remission, how this
remission is maintained in the absence of continuous IFN
treatment in patients with persistent molecular disease remains
unknown. We hypothesized that IFN induces a self-renewing
population of leukemia-specific CTL that contribute to remission
in the absence of continuous therapy. We have previously shown
that although the frequency of PR1-CTL in the peripheral blood
of healthy HLA-A2+ donors are below the limits of detection by
tetramer analysis, they can be expanded in vitro [34]. We have
also shown that PR1-CTL are not detectable in newly diagnosed
CML patients or in patients that do not respond to treatment
with IFN and that PR1-CTL contribute to T cell mediated anti-
CML immunity [16]. Furthermore, a recent study by Buchert
et al demonstrated that PR1-CTL persist after withdrawal of
imatinib in patients that continued to receive maintenance IFN
and was associated with long-term CR [29]. In that study, PR1-
CTL immunity was not assessed in two patients that achieved
complete molecular remission in IFN maintenance. Here, we
extend these observations and present three findings that provide
evidence that functional memory PR1-CTL contribute to anti-
leukemia immunity after IFN withdrawal. First, we show that
PR1-CTL are maintained in IFN-sensitive CML patients for 6
months to 7 years after stopping all treatment. Second, we show
that while all lymphocyte differentiation phenotypes are present
in PR1-CTL, the CD45RA-CD28+CCR76CD57- PR1-CTL
expand preferentially after antigen stimulation, which is consis-
tent with a self-renewing central memory T cell population.
Finally, we show that PR1-CTL produce IFNc in response to
PR1 peptide stimulation in a recall response. In 3 patients that
relapsed, however, PR1-CTL were unable to produce IFNc prior
to or concomitant with relapse of CML. Combined with previous
studies showing PR1-CTL kill CML and contribute to CR in
IFN-sensitive CML patients [16], our current study suggests that
PR1-CTL expand during IFN therapy and that IFN may
facilitate long-term persistence of PR1-CTL in a subset of
CML patients that remain disease-free after all treatment has
stopped.
Our data showing the persistence of functional PR1-CTL in
patients 1 to 7 after IFN withdrawal extend the results of a
previous study that showed measurable PR1-CTL by tetramer
staining in 4/4 patients 3 years after cessation of IFN treatment
[35]. Memory T cells are characterized by expression of the
CD45RO isoform [36], but a fraction of memory cells express
CD45RA [37,38]. Previous studies with antigen-specific T cells for
the CMV-derived pp65-A2 peptide have shown that upon
stimulation, cell division is predominantly restricted to the
Figure 4. The phenotype of PR1-CTL changes from predominantly naı ¨ve to memory upon stimulation. PBMC from patient 3 were
labeled with CFSE, stimulated for 80 hours, then labeled with antibodies for analysis of surface phenotype by FACS to determine naı ¨ve (N), central
memory (CM), and effector memory (EM) cells, as described in the text. (A) The left panel shows the absolute number of PR1-CTL that proliferate after
T cell receptor (TCR) stimulation with OKT3 and anti-CD28 antibodies. (B) The right panel depicts the percentage of PR1-CTL that were phenotypically
categorized as N, CM, or EM before (time 0) and after (time 80 hrs) TCR stimulation. Prior to stimulation, PR1-CTL were predominantly naı ¨ve (N)
phenotype and following stimulation PR1-CTL were predominantly CM phenotype.
doi:10.1371/journal.pone.0011770.g004
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capable of secreting IFNc upon antigen-specific stimulation,
consistent with our findings. Furthermore, CD45RA-CCR7-
CD8+ T cells that are at a more advanced stage of differentiation,
though not senescent, can re-acquire CCR7 and/or CD45RA
upon antigen-specific stimulation [30]. In our study, all patients
that remained in remission had PR1-CTL that were enriched for
CD8+CD45RA+CCR7+, with a smaller fraction that were
CD8+CD45RA-CCR7+. In order to determine whether PR1-
CTL were capable of dividing, we sorted the cells to .95% purity
and stimulated them in a proliferation assay. Consistent with the
characteristics of memory T cells, we found that the effector and
central memory PR1-CTL proliferated robustly, supporting our
hypothesis that IFN treatment induces a self-renewing population
of leukemia-specific CTL that may help to maintain anti-leukemia
immunity and remission in the absence of ongoing treatment.
Interestingly, we found that a higher frequency of PR1-CTL with
a naı ¨ve T cell phenotype proliferated as compared with the overall
CD8+ cells while the average number of divisions undergone was
similar to that of memory PR1-CTL (Figure 5). Although
CD45RA+CCR7+ CTL includes naı ¨ve T cells, the high frequency
of PR1-CTL in the peripheral blood of IFN-sensitive patients, the
production of IFNc in a recall response and the ability to
proliferate strongly suggests that this may be a re-expanded
population rather than an antigen-inexperienced one. Future
studies should discern whether these phenotypically naı ¨ve cells are
recent thymic emigrants or whether they come from self-renewing
central memory stem cells [39] that re-express CD45RA. Since
PR1 is a self-antigen derived from P3 and NE, proteins that are
expressed in myeloid cells, the antigen required for maintaining
Figure 5. PR1-CTL of all differentiation phenotypes proliferate. Lin- CD8+ cells from patient 4 were sorted into effector memory (EM), central
memory (CM), terminally differentiated (TD) and naı ¨ve (N) populations, then labeled with CFSE and stimulated with OKT3 + anti-CD28 antibodies.
After 80 hours, cells were labeled with PR1/HLA-A2 tetramer and analyzed for evidence of proliferation by CFSE dilution. (A) The upper panel shows
the frequency of proliferating PR1-CTL compared to total CD8+ T cells, and (B) the lower panel shows proliferation indices of PR1-CTL compared to
total CD8+ T cells.
doi:10.1371/journal.pone.0011770.g005
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tively, PR1 might derive from residual small fraction of leukemia
cells that over-express P3 or NE, or it is possible that the level of
PR1 expression on non-leukemia cells is sufficient to maintain a
PR1-CTL population.
The loss of function of PR1-CTL prior to relapse (Figure 6)
suggests that broader anti-CML immunity might be lost prior to
disease relapse. We were unable to address whether loss of
function is a broad-based phenomenon that applies to other LAAs
or whether this is restricted to the PR1 peptide antigen due to
limited availability of patient material. However, we observed that
at each time-point studied, CD8+ T cells produced IFNc in
response to stimulation with SEB, suggesting that loss of function is
antigen-specific and might therefore apply to immunity against
other LAAs. Following relapse, patients 2, 6, and 7 were treated
with imatinib, achieved CCR, and PR1-CTL again increased.
There are contradictory reports on the effect of imatinib on T cell
function and although many investigators have described the
immunosuppressive effects of imatinib on both T cells and
dendritic cells [40,41,42], other reports indicate that imatinib
does not induce apoptosis of T cells and that its inhibitory effects
on T cell proliferation and function are reversible after removal of
the drug [43,44]. While enhanced IFNc production by T cells has
also been reported in IFN-refractory CML patients treated with
imatinib [45], a more recent study showed distinct immunological
status of patients treated with imatinib and IFN [46]. In our study,
we observed that following treatment with imatinib, both PR1-
CTL and pp65-specific CTL from patients 2, 6, and 7 produced
IFNc when stimulated. Since the cells were studied in vitro,w e
cannot rule out inhibitory effects of imatinib in vivo. However, our
data are consistent with studies showing that imatinib does not
induce T cell apoptosis [43] and that treatment with IFN after
cessation of imatinib is associated with an induction of PR1-CTL
[29].
Although the data from this study shows that functional
immunity to PR1 persists during unmaintained remission of
CML, it does not demonstrate that PR1-CTL immunity is the sole
driver of sustained molecular remission. Because of limited
availability of patient material, we did not study immunity to
other known CML antigens such as WT1 or the BCR-ABL fusion
region peptides, but we would expect that CTL immunity against
these and perhaps other leukemia antigens should be similarly
increased. Furthermore, because we did not demonstrate that
PR1-CTL were directly cytotoxic against CML cells or against
LSC in particular, it is possible that the observed changes in the
number of PR1-CTL may merely reflect changes in the leukemia
burden. For instance, we have shown that CML shapes host
immunity by preferential elimination of high avidity PR1-CTL,
Figure 6. Loss of functional PR1-CTL precedes cytogenetic relapse in patient 2. Staining with the PR1/HLA-A2 tetramer was done to
determine the percentage of high- and low-avidity PR1-CTL as described in the methods. In the top panel, PR1-CTL are defined as CD8+ Lin- PR1/
HLA-A2-tetramer+. The center panel shows the percentage of CD8+ lymphocytes that produce IFNc in response to stimulation with 0.2 mM PR1
peptide after subtracting the percentage of CD8+ cells that produced IFNc in the absence of stimulation. Non-stimulated cells were used to adjust
background. Stimulation with SEB superantigen was used to confirm that the lymphocytes were not anergic. The lower panel shows the frequency of
CD8+ cells that produce IFNc in response to SEB stimulation.
doi:10.1371/journal.pone.0011770.g006
T Cells Maintain CML Remission
PLoS ONE | www.plosone.org 10 July 2010 | Volume 5 | Issue 7 | e11770which are more cytolytic against CML than low avidity PR1-CTL,
and the data in Figure 6 support these previous observations [24].
In summary, our data provide evidence that PR1 leukemia
antigen-specific CTL-mediated anti-tumor immunity after IFN
withdrawal may contribute to continued CR in the absence of
subsequent treatment, including withdrawal of IFN. This study
extends the observations of Buchert et al and suggests that long-
term persistence of tumor-reactive CTL may be necessary to
control the outgrowth of residual leukemia cells and prevent
relapse. Subsequent prospective studies should examine whether
loss of functional PR1-CTL immunity predicts relapse. Strategies
to boost immunity by vaccination with known leukemia-antigens
in combination with IFN or strategies for IFN maintenance
therapy after imatinib treatment, as suggested by the results of a
prospective clinical trial in patients treated with imatinib and IFN
[29], might improve responses in patients.
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